EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study

Zhipeng Sun, Hai Xu, Lei Yang, Xiaojuan Wang, Bin Shu, Ming Yang, Zhizhong Ren, Canhong Xiang, Yuewei Zhang, Shizhong Yang

BioScience Trends · 2024

DOI: 10.5582/bst.2024.01286 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BioScience Trends, 2024. Verfasst von Zhipeng Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Institute for Precision Medicine, Key Laboratory of Digital Intelligence Hepatolo…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsImmune Checkpoint InhibitorsHumansRetrospective StudiesMaleFemaleMiddle AgedFluorouracilLeucovorinAgedOxaliplatinOrganoplatinum CompoundsDeoxycytidineAdultQuinolinesProgrammed Cell Death 1 ReceptorGemcitabineCisplatinOxonic AcidTegafurPhenylurea Compounds

Stichwörter der Autor:innen

advanced biliary tract cancerhepatic arterial infusion chemotherapy (HAIC)programmed cell death protein-1 (PD-1)systemic chemotherapy

Substanzen

FluorouracilLeucovorinOxaliplatinOrganoplatinum CompoundslenvatinibDeoxycytidineQuinolinesProgrammed Cell Death 1 ReceptorGemcitabineCisplatin

Autor:innen und Institutionen

  • Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Institute for Precision Medicine, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), Tsinghua University; Research Unit of Prec…
  • Department of Hepatopancreatobiliary Surgery, Affiliated Hospital, School of Clinical Medicine, Qinghai University, Xining, Qinghai, China.

Zitieren

APA

Sun, Z., Xu, H., Yang, L., Wang, X., Shu, B., Yang, M., Ren, Z., Xiang, C., Zhang, Y., & Yang, S. (2024). mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study. BioScience Trends. https://doi.org/10.5582/bst.2024.01286

Vancouver

Sun Z, Xu H, Yang L, Wang X, Shu B, Yang M, et al. mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study. BioScience Trends. 2024. doi:10.5582/bst.2024.01286

BibTeX
@article{Sun2024,
  author = {Sun, Zhipeng and Xu, Hai and Yang, Lei and Wang, Xiaojuan and Shu, Bin and Yang, Ming and Ren, Zhizhong and Xiang, Canhong and Zhang, Yuewei and Yang, Shizhong},
  title = {mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC/GS/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study},
  journal = {BioScience Trends},
  year = {2024},
  doi = {10.5582/bst.2024.01286}
}
Kostenlos starten →